Clinical Trial

A Phase I Study of YK012 in Primary Membranous Nephropathy

Name: A Phase I Study of YK012 in Primary Membranous Nephropathy — clinical trial record (NCT07234474)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics(PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (pMN).

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-11-14.

Trial Details

NCT Number	NCT07234474
Lead Sponsor	Excyte Biopharma Ltd
Conditions	Primary Membranous Nephropathy
Enrollment	66 participants
Start Date	2026-10
Primary Completion	2027-11 (estimated)
Study Completion	2028-02 (estimated)
Updated on ClinicalTrials.gov	2026-02-05